De novo belatacept does not reduce the rate of skin cancer in renal transplant recipients compared to standard therapy.

Autor: Jew OS; Department of Dermatology, Duke University Health System, Durham, North Carolina., Liu WW; Duke University School of Medicine, Durham, North Carolina., Stamey C; Department of Dermatology, Duke University Health System, Durham, North Carolina., Kheterpal M; Department of Dermatology, Duke University Health System, Durham, North Carolina., Myers SA; Department of Dermatology, Duke University Health System, Durham, North Carolina., Ellis MJ; Department of Medicine, Duke University Health System, Durham, North Carolina., Byrns J; Department of Pharmacy, Duke University Health System, Durham, North Carolina., Wheless L; Tennessee Valley Healthcare System VA Medical Center, Nashville, Tennessee; Department of Dermatology, Vanderbilt University Medicine Center, Nashville, Tennessee., Whitley MJ; Department of Dermatology, Duke University Health System, Durham, North Carolina. Electronic address: Melodi.whitley@duke.edu.
Jazyk: angličtina
Zdroj: Journal of the American Academy of Dermatology [J Am Acad Dermatol] 2024 Oct; Vol. 91 (4), pp. 720-722. Date of Electronic Publication: 2024 Jun 04.
DOI: 10.1016/j.jaad.2024.05.068
Abstrakt: Competing Interests: Conflicts of interest None disclosed.
Databáze: MEDLINE
Externí odkaz: